Modulation of hepatitis b virus (hbv) expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsEric E. SWAYZE, Susan M. Freier, Michael L. McCaleb
Life of this patent
Estimating the term…
Abstract
Disclosed herein are antisense compounds and methods for decreasing HBV mRNA, DNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate HBV-related diseases, disorders or conditions.
Claims23
1-36. (canceled)
A compound comprising a modified oligonucleotide consisting of 10 to 30 linked nucleosides having a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases 100% complementary to an equal length portion of nucleobases 1577-1506, wherein the nucleobase sequence of the modified oligonucleotide is complementary to SEQ ID NO:1.
43-44. (canceled)
46-47. (canceled)
(canceled)
53-54. (canceled)
61-72. (canceled)
Dependencies are inferred from the claim text.